{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+Injection&page=8", "query": { "intervention": "Sham Injection", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 372, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+Injection&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+Injection&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T03:57:21.265Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01527500", "title": "Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Geographic Atrophy", "Age-related Macular Degeneration" ], "interventions": [ { "name": "LFG316", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" }, { "name": "LFG316 Lower dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 158, "start_date": "2012-01-25", "completion_date": "2015-06-24", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01527500" }, { "nct_id": "NCT02745119", "title": "Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Geographic Atrophy" ], "interventions": [ { "name": "Lampalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 994, "start_date": "2016-07-21", "completion_date": "2018-01-31", "has_results": true, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 122, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 103 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02745119" }, { "nct_id": "NCT06011798", "title": "Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema", "Retinal Disease", "Macular Edema", "Diabetes Mellitus", "Diabetic Retinopathy", "Retinal Degeneration", "Retinal Diseases", "Eye Diseases", "Edema" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "foselutoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Unity Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2023-08-23", "completion_date": "2025-04-08", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 19, "location_summary": "Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06011798" }, { "nct_id": "NCT01940900", "title": "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "E10030", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "E10030 sham intravitreal injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 627, "start_date": "2013-08", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 49, "location_summary": "Tucson, Arizona • Fresno, California • La Jolla, California + 43 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940900" }, { "nct_id": "NCT01049919", "title": "Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Critical Limb Ischemia", "Peripheral Arterial Disease", "Peripheral Vascular Disease" ], "interventions": [ { "name": "Bone marrow concentration device", "type": "DEVICE" }, { "name": "Placebo procedure (sham)", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Zimmer Biomet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 153, "start_date": "2010-06", "completion_date": "2020-02", "has_results": true, "last_update_posted_date": "2021-05-28", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01049919" }, { "nct_id": "NCT03802630", "title": "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Branch Retinal Vein Occlusion" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2019-07-02", "completion_date": "2021-07-26", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03802630" }, { "nct_id": "NCT01474382", "title": "Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dental Anesthesia", "Anesthesia, Local", "Anesthesia, Reversal" ], "interventions": [ { "name": "OraVerse", "type": "DRUG" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novocol Pharmaceutical of Canada, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "5 Years", "sex": "ALL", "summary": "2 Years to 5 Years" }, "enrollment_count": 150, "start_date": "2012-02", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2014-08-29", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 7, "location_summary": "San Francisco, California • Indianapolis, Indiana • Columbus, Ohio + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01474382" }, { "nct_id": "NCT05654441", "title": "Body and Social Behavior", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psychology, Social", "Inflammation", "Defeat, Social", "Interaction, Social" ], "interventions": [ { "name": "Influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 104, "start_date": "2022-10-17", "completion_date": "2023-12-15", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05654441" }, { "nct_id": "NCT03629275", "title": "Investigation of Neural Stem Cells in Ischemic Stroke", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ischemic Stroke", "Chronic Stroke", "Hemiparesis", "Arm Paralysis" ], "interventions": [ { "name": "CTX0E03 Drug Product and delivery device", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "ReNeuron Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 15, "start_date": "2018-08-31", "completion_date": "2021-03-02", "has_results": false, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03629275" }, { "nct_id": "NCT03810313", "title": "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Central Retinal Vein Occlusion" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 493, "start_date": "2019-07-03", "completion_date": "2021-07-26", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-10-19T03:57:21.265Z", "location_count": 30, "location_summary": "Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03810313" } ] }